Clinical trials: Pediatric Pulmonary Hypertension
Pulmonary Hypertension, Congenital Heart Disease
Image-based Multi-scale Modeling Framework of the Cardiopulmonary System: Longitudinal Calibration and Assessment of Therapies in Pediatric Pulmonary Hypertension
This study looks to develop a multi-scale computational model of Pulmonary Hypertension, this clinical model will be calibrated using longitudinal, retrospectively and prospectively acquired human clinical data.
- Conditions
- Pulmonary Hypertension, Congenital Heart Disease, Pediatric Congenital Heart Disease
- Trial name
- NCT03564522
- Testing
- cardiac catheterization, Cardiac MRI
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Michigan
Pulmonary Hypertension
Sedation With Dexmedetomidine During Cardiac Catheterization
Clinical dose escalation drug trial to evaluate the effect of 3 different doses of dexmedetomidine on the pulmonary vascular bed in pediatric subjects with elevated pulmonary vascular resistance (PVR).
- Trial name
- NCT01072643
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Aruna Nathan
Pulmonary Arterial Hypertension
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and effectiveness of iloprost for PAH in children who are between the ages of 3 and 18 years old.
- Trial name
- NCT00453414
- Testing
- Iloprost Inhalation Solution (Ventavis)
- Where
- 2 sites in United States
- Sponsor
- Actelion
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Preserving Kidney Function in Children With Chronic Kidney Disease
Pediatric chronic kidney disease (CKD) results from health conditions that reduce kidney function for >3 months. It can progress to end-stage kidney disease (ESKD), which requires dialysis or kidney transplant.
- Conditions
- Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease
- Trial name
- PRESERVE (NCT05169411)
- Testing
- Blood pressure, Urine protein
- Where
- United States
- Volunteers
- 20,240 people
- Sponsor
- Children's Hospital of Philadelphia
Pediatric Pulmonary Hypertension
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better…
- Trial name
- MoD (NCT04039464)
- Testing
- Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Johns Hopkins University
Pulmonary Arterial Hypertension
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.
- Trial name
- NCT01484431
- Testing
- Tadalafil- Tablet or Oral suspension
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Pulmonary Arterial Hypertension
Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension
The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial hypertension (PAH) <12 years of age.
- Trial name
- FUTURE 3 (NCT01223352)
- Testing
- bosentan
- Volunteers
- 64 people
- Sponsor
- Actelion
Hypertension, Pulmonary
Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension
The TOPP-2 registry is an international, non-interventional, prospective registry including children and adolescents newly diagnosed with pulmonary hypertension (PH) to gain further insights in the disease course and long-term…
- Trial name
- TOPP-2 (NCT02610660)
- Where
- 32 sites in United States, Australia and 16 more
- Volunteers
- 388 people
- Sponsor
- Association for Pediatric Pulmonary Hypertension
Pulmonary Arterial Hypertension
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension
This is a prospective pilot study to assess the plasma levels of particular proteins involved in the transforming growth factor beta (TGF-β) pathway and its down stream regulators, CHIP, as well as micro RNA molecules in subjects…
- Trial name
- NCT04489251
- Testing
- Protein Elisa analysis, microRNA analysis, whole exome sequencing
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical College of Wisconsin
Pulmonary Hypertension
Insights Into Pediatric Pulmonary Hypertension: A Real-World Registry of Epidemiology and Outcomes
Pediatric pulmonary hypertension (PH) shares similarities with PH in adulthood, but specific differences still require unique approaches.
- Trial name
- INSPIRE-PPH (NCT07495774)
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Guangdong Provincial People's Hospital
Pulmonary Hypertension
iTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH
Children with pulmonary hypertension (PH) engage in less physical activity than their peers. This is a concern since adult data support exercise as a non-pharmacologic treatment for PH.
- Trial name
- iTONE (NCT05442671)
- Testing
- Exercise intervention
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Children's Hospital of Philadelphia
Hypertension;Pulmonary;Primary
Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension
This study plans to learn more about activity levels in children with pulmonary hypertension. Pulmonary hypertension is a condition where the pressure in the lungs is higher than normal. This can affect the person's heart.
- Trial name
- NCT04745000
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Pulmonary Hypertension
Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery
Inhaled nitrous oxide (iNO) will be compared to aerosolized iloprost (ILO) in pediatric patients after cardiac surgery with pulmonary hypertension.
- Trial name
- NCT00235521
- Testing
- aerosolized iloprost
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Heidelberg University
Pulmonary Arterial Hypertension
Exercise Capacity Respiratory Muscle Strength Dyspnea and Physical Activity in Pediatric Pulmonary Arterial Hypertension
The primary aim of this study was to evaluate exercise capacity, respiratory muscle strength, pulmonary function, dyspnea and physical activity levels in pediatric PAH patients and compare them with healthy controls.
- Trial name
- NCT05124015
- Where
- Turkey (Türkiye)
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Gazi University
Pulmonary Vascular Resistance Abnormality
PV Loop and Pulmonary Hypertension
The right ventricular (RV) systolic function is a key determinant of outcome in patients with pulmonary hypertension and elevated pulmonary vascular resistance.
- Trial name
- NCT05484596
- Testing
- Measuring VA Coupling
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Hythem Nawaytou
Hypertension, Pulmonary
Efficacy and Safety of Ambrisentan in Children 8-18yrs
A 6-month (24-week), randomized, open label evaluation of the safety, tolerability, and efficacy of a high and low dose ambrisentan (adjusted for body weight) treatment group in subjects aged 8 years up to 18 years with pulmonary…
- Trial name
- NCT01332331
- Testing
- Ambrisentan - low dose, Ambrisentan - high dose
- Where
- 24 sites in United States, Argentina and 7 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
FUTURE 3 Study Extension
The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension…
- Trial name
- FUTURE 3 Ext (NCT01338415)
- Testing
- Bosentan
- Where
- 36 sites in United States, Australia and 16 more
- Volunteers
- 58 people
- Sponsor
- Actelion
Congenital Heart Disease, Pulmonary Arterial Hypertension
Biomarkers in Pediatric Congenital Heart Disease and PAH
Nowadays, biomarkers are broadly used in clinical practice. Blood-derived biomarkers fulfil an important role in the field of cardiology. However, most biomarkers have been investigated for adult left ventricular disease.
- Trial name
- NCT04130243
- Testing
- Blood test
- Where
- Netherlands
- Volunteers
- 380 people
- Sponsor
- University Medical Center Groningen
Pulmonary Arterial Hypertension
Mobile Health Intervention to Improve Exercise in Pediatric PH
Children and adults with pulmonary arterial hypertension (PAH) have severely reduced daily activity compared to healthy populations.
- Trial name
- MhOVE-PPH (NCT06549452)
- Testing
- mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University Medical Center
Hypertension, Pulmonary
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
- Trial name
- NCT02576002
- Testing
- Assigned pulmonary hypertension medication
- Where
- United States
- Volunteers
- 2,691 people
- Sponsor
- Bayer